Holen Sie sich die Stockscreener-App
8.13
0.49%
-0.04
Schlusskurs vom Vortag:
$8.17
Offen:
$8.13
24-Stunden-Volumen:
115.65K
Relative Volume:
1.33
Marktkapitalisierung:
$211.40M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.1633
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
-8.14%
1M Leistung:
-20.22%
6M Leistung:
-35.98%
1J Leistung:
-58.69%
1-Tages-Spanne:
$7.945
$8.29
1-Wochen-Bereich:
$7.88
$8.89
52-Wochen-Spanne:
$7.75
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
8.13 | 212.44M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
How Cartesian Therapeutics Inc. (1S70) stock expands through international marketsEarnings Recap Report & Weekly Watchlist for Consistent Profits - newser.com
Cartesian Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Is a relief rally coming for Cartesian Therapeutics Inc. holdersJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Is Cartesian Therapeutics Inc. trending in predictive chart modelsQuarterly Portfolio Review & Weekly Hot Stock Watchlists - newser.com
Key metrics from Cartesian Therapeutics Inc.’s quarterly dataPortfolio Update Summary & Consistent Profit Trading Strategies - newser.com
How Cartesian Therapeutics Inc. stock performs during Fed tightening cyclesDay Trade & AI Forecasted Entry/Exit Points - newser.com
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investorsJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - newser.com
Is Cartesian Therapeutics Inc. a candidate for recovery playTrade Volume Summary & AI Enhanced Trading Alerts - newser.com
Will Cartesian Therapeutics Inc. price bounce be sustainableVolume Spike & Daily Growth Stock Tips - newser.com
How to read the order book for Cartesian Therapeutics Inc.2025 Market WrapUp & Community Trade Idea Sharing - newser.com
Will Cartesian Therapeutics Inc. stock outperform tech sector in 2025Entry Point & High Conviction Buy Zone Picks - newser.com
Working capital per share of Cartesian Therapeutics, Inc. – FWB:1S70 - TradingView
Is Cartesian Therapeutics Inc. stock near bottom after declineWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Combining price and volume data for Cartesian Therapeutics Inc.Quarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Is Cartesian Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Setups & Daily Volume Surge Trade Alerts - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock gain from green policiesBear Alert & Verified Trade Idea Suggestions - newser.com
Cartesian Therapeutics, Inc. (RNAC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Singapore
Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday - MarketBeat
Cartesian Therapeutics Announces Leadership Changes - The Globe and Mail
Ranking Cartesian Therapeutics Inc. among high performing stocks via tools2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
What indicators show strength in Cartesian Therapeutics Inc.Portfolio Risk Summary & Daily Volume Surge Signals - newser.com
Cartesian Therapeutics Appoints Carsten Brunn, Ph.D., as Board Chairman - citybiz
Cartesian Therapeutics, Inc. Announces Board and Committee Changes, Effective from October 29, 2025 - MarketScreener
Cartesian Therapeutics (RNAC) Grants Stock Options to New Employ - GuruFocus
Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors - The Manila Times
Cartesian Therapeutics Announces Board Changes - TradingView
[8-K] Cartesian Therapeutics, Inc. Reports Material Event | RNAC SEC FilingForm 8-K - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) grants options at $8.85 and $8.20 inducement - Stock Titan
Cartesian Therapeutics (NASDAQ: RNAC) appoints CEO Carsten Brunn as chairman - Stock Titan
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):